Kiora Pharmaceuticals Inc (KPRX) - Total Assets
Based on the latest financial reports, Kiora Pharmaceuticals Inc (KPRX) holds total assets worth $21.23 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore KPRX debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Kiora Pharmaceuticals Inc - Total Assets Trend (2012–2025)
This chart illustrates how Kiora Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See net assets of Kiora Pharmaceuticals Inc for net asset value and shareholders' equity analysis.
Kiora Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Kiora Pharmaceuticals Inc's total assets of $21.23 Million consist of 89.7% current assets and 10.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 35.9% |
| Accounts Receivable | $3.32 Million | 13.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.06 Million | 8.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Kiora Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Kiora Pharmaceuticals Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kiora Pharmaceuticals Inc's current assets represent 89.7% of total assets in 2025, an increase from 87.6% in 2012.
- Cash Position: Cash and equivalents constituted 35.9% of total assets in 2025, down from 84.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 13.7% of total assets.
Kiora Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Kiora Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Kiora Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.68 | 5.14 | 3.07 |
| Quick Ratio | 6.68 | 5.14 | 3.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $15.88 Million | $21.83 Million | $2.98 Million |
Kiora Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Kiora Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.67 |
| Latest Market Cap to Assets Ratio | 0.44 |
| Asset Growth Rate (YoY) | -33.5% |
| Total Assets | $24.25 Million |
| Market Capitalization | $10.68 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kiora Pharmaceuticals Inc's assets below their book value (0.44x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Kiora Pharmaceuticals Inc's assets decreased by 33.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kiora Pharmaceuticals Inc (2012–2025)
The table below shows the annual total assets of Kiora Pharmaceuticals Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $24.25 Million | -33.52% |
| 2024-12-31 | $36.48 Million | +166.08% |
| 2023-12-31 | $13.71 Million | -26.59% |
| 2022-12-31 | $18.68 Million | -7.21% |
| 2021-12-31 | $20.13 Million | +31.53% |
| 2020-12-31 | $15.30 Million | +51.34% |
| 2019-12-31 | $10.11 Million | -29.19% |
| 2018-12-31 | $14.28 Million | -0.17% |
| 2017-12-31 | $14.31 Million | +47.01% |
| 2016-12-31 | $9.73 Million | +2.34% |
| 2015-12-31 | $9.51 Million | +576.00% |
| 2014-12-31 | $1.41 Million | +103.19% |
| 2013-12-31 | $692.19K | -70.45% |
| 2012-12-31 | $2.34 Million | -- |
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also deve… Read more